来自MSN12 小时
Daily Oral Edaravone for ALS No Better Than On/Off Regimen
Daily oral edaravone (Radicava ORS) was not superior to the FDA-approved on/off regimen in amyotrophic lateral sclerosis (ALS ...
Medscape3 天
Myasthenia Gravis: Similar Symptoms in Relatives Raise Question of Genes
In one of the case reports, a 75-year-old White man with hereditary coagulopathy presented with myasthenic crisis in the setting of acute pulmonary embolism. Chronic symptoms included diplopia, ptosis ...
Medscape4 天
First-in-Class B-Cell Depleting Agent Promising for Myasthenia Gravis
A first-in-class anti-CD19 B-cell depleting agent was safe and demonstrated superior efficacy vs placebo in patients with ...
PharmiWeb6 天
Nipocalimab demonstrates sustained disease control in adolescents living with generalised ...
For immediate release Nipocalimab demonstrates sustained disease control in adolescents living with generalised myasthenia ...
PharmiWeb6 天
UCB showcases new data for gMG management at the 2…
UCB will contribute 14 presentations, including an oral presentation, selected to feature across the AANEM and MGFA meeting, emphasizing UCB's leadership in neuromuscular researchPresentations ...
Le Lézard6 天
Mitsubishi Tanabe Pharma America to Showcase ALS Research at 2024 AANEM Annual Meeting
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced three presentations at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting being held in ...
Nipocalimab demonstrates sustained disease control in adolescents living with generalized ...
Johnson & Johnson (NYSE: JNJ) today announced positive results from the Phase 2/3 Vibrance-MG study of nipocalimab in anti-AChRa positive adolescents (aged 12 – 17 years) living with generalized ...